GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (MEX:BNGO) » Definitions » Net Issuance of Debt

Bionano Genomics (MEX:BNGO) Net Issuance of Debt : MXN-937.4 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bionano Genomics Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Bionano Genomics's net issuance of debt for the three months ended in Sep. 2024 was MXN-59.4 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Sep. 2024 was MXN-937.4 Mil.

Bionano Genomics Net Issuance of Debt Historical Data

The historical data trend for Bionano Genomics's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionano Genomics Net Issuance of Debt Chart

Bionano Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Issuance of Debt
Get a 7-Day Free Trial 185.21 -93.95 -307.81 -0.70 -153.57

Bionano Genomics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 -152.99 -608.70 -116.37 -59.37

Bionano Genomics Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-937.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionano Genomics Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionano Genomics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (MEX:BNGO) » Definitions » Net Issuance of Debt
Comparable Companies
MHUA YBGJ DXR POCI RVP NSTG PDEX MLSS UEEC OMIC ISRG XPAR:EL BDX XSWX:ALC TSE:7741 WST OCSE:COLO B RMD TSE:4543 XSWX:STMN
Traded in Other Exchanges
BNGO:USA 0A4K:UK
Address
9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Website
https://www.bionano.com
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.